Kardigan, a newly launched biotech company, has secured $300 million in Series A funding to pioneer breakthrough treatments for cardiovascular diseases. The funding round was led by Perceptive Advisors, Arch Venture Partners, and Sequoia Heritage, signaling strong investor confidence in the company’s mission to redefine care for heart conditions worldwide.
With cardiovascular diseases remaining the leading cause of mortality globally, Kardigan aims to develop both preventive and curative therapies. The company plans to leverage its proprietary cardiac-focused discovery platform, which integrates advanced tools to better understand disease mechanisms and personalize treatments. This innovative approach will enhance the precision of matching patients to therapies, improving outcomes across its pipeline of late-stage candidates.
The leadership team is composed of seasoned experts, many of whom played pivotal roles at MyoKardia, the cardio-focused biotech acquired by Bristol Myers Squibb for $13 billion in 2020. Kardigan is led by CEO and Chair Tassos Gianakakos, former CEO of MyoKardia, alongside co-founders Jay Edelberg, M.D., Ph.D. (Chief Medical Officer), Bob McDowell, Ph.D. (Chief Scientific Officer), MyoKardia co-founder Leslie Leinwand, Ph.D., and prominent cardiologist Beth McNally, M.D., Ph.D.
“Our cardiac intelligence model allows us to share and integrate data across programs, increasing efficiency and our chances of success,” said Gianakakos. “While current treatments have made strides, they fail to fully address the growing global health emergency. Kardigan is committed to transforming the landscape of cardiovascular care.”
Kardigan’s immediate focus includes developing therapies for primary and secondary cardiomyopathies, which are key drivers of heart failure. The company is also employing a strategy that combines its proprietary R&D platform with in-licensing and acquisitions to expand its portfolio.
The startup’s vision is rooted in its mission to eliminate cardiovascular diseases as the leading cause of death. “With our dedicated team and robust resources, we are uniquely positioned to address the unmet needs in cardiology and create a healthier future for millions,” Gianakakos added.
As Kardigan embarks on its journey, it seeks to bring transformative therapies to patients, ensuring that heart diseases no longer hold the top spot as the world’s most significant health challenge.
Discover more from FundingBlogger
Subscribe to get the latest posts sent to your email.